Navigation Links
SpectraScience Announces Results of Annual Shareholder Meeting
Date:9/22/2009

SAN DIEGO, Sept. 22 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC Bulletin Board: SCIE), a San Diego based medical device company, held its Annual Meeting of the Shareholders for the fiscal year ended 2008 at 9:00 am local time September 21, at the Del Mar Hilton in Del Mar, California. The business matters considered and acted upon at the meeting included (a) a vote to set the number of directors of the Company at six and election of six directors, and (b) amend the Company's Articles of Incorporation.

Only shareholders of record at the close of business on August 14, 2009 were entitled to vote at the meeting. Approximately 87% of the shares eligible to vote were cast in the above-mentioned matters. Approximately 99% of the shares were voted in favor of setting the number of directors of the Company at six and electing the six nominated directors, and approximately 96% were voted in favor of amending the Articles of Incorporation.

Also at the Annual Meeting, Jim Hitchin, President and Chief Executive Officer of SpectraScience, Inc., gave a presentation. Key highlights from the presentation included:

  • An overview of the business of SpectraScience, its technology and advantages including higher sensitivity in cancer screening, instantaneous detection of diseased tissue, the opportunity for treatment at the time of original patient visit and the ability to lower pathology costs, all leading to better overall patient care;
  • Highlights for the year including FDA approvals for WavSTAT(R) (colon cancer screening) and LUMA(R) (cervical cancer screening), EU approval for WavSTAT (colon & esophageal cancer screening), FDA clearance for manufacturing facility, the recently announced FDA clearance for a new WavSTAT platform, and the establishment of a European distribution network for WavSTAT; and
  • An update on the WavSTAT clinical trials (esophageal cancer screening) which are in process at Boston University, the Mayo Clinic, the Kansas City VA Hospital and the University of Southern California. The Company is also beginning esophageal clinical trials at multiple sites in the European Union.

Mr. Hitchin also discussed catalysts for the Company's growth moving forward, including: the growing and aging population; the increasing recognition of the value of testing as a way to improve health and reduce the overall costs of healthcare through early detection and prevention; the increasing access to tests that leverage advances in technology and cost efficiencies; the expanding role of diagnostics (early detection and intervention lead to better medical and economic outcomes); expansion of distribution and the addition of software applications to the technology platform to create leverage in the model for physicians and clinics.

Among those present at the meeting were members of the Company's board of directors, which includes Jim Hitchin, Stan Pappelbaum, M.D., Chet Sievert, F. Duwaine Townsen, and the Honorable Tommy Thompson. At the conclusion of the meeting, Gov. Thompson commented that, "It is a privilege to be associated with a company with as much promise as SpectraScience has in contributing to the fight against cancer. Jim Hitchin is doing a fantastic job developing this business and positioning the company to drive shareholder value."

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.

About SpectraScience, Inc.

SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. The Company's LUMA imaging technology has received FDA approval for an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available in the market today.

    Contact:

    SpectraScience, Inc.
    Jim Hitchin, Chief Executive Officer
    (858) 847-0200 x201

    Hayden Communications
    Investor Relations
    Todd Pitcher
    (858)-518-1387


'/>"/>
SOURCE SpectraScience, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. SpectraScience Receives Final European Certification
2. SpectraScience Acquires Luma Imaging Corporation
3. SpectraScience, Inc. Retains Hayden Communications
4. SpectraScience Secures Distribution for WavSTAT(R) System in Czech Republic
5. SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in Italy
6. SpectraScience Adds Industry Veteran to Executive Team
7. SpectraScience Awarded Patent for Correcting Image Misalignment
8. SpectraScience Delivers Cancer Diagnosis System to Mayo Clinic and UCSD/VA for Detecting Esophageal Dysplasia in Patients
9. SpectraScience Announces Updates
10. SpectraScience Awarded European Patent for Its Optical Biopsy System for Tissue Diagnosis
11. SpectraScience Awarded U.S. Patent 7,459,696 for its Unique Methods of Calibrating Spectral Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , , , WHEN: ... , , , , LOCATION: , , , Online, with ... , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice ... Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... industry is witnessing an exceptional era. Several new demand spaces, such ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma ... as the company,s second affiliate in Latin America . ... ... Astellas Farma Colombia ... ...
(Date:6/23/2016)... PRINCETON, N.J. , June 23, 2016  Guerbet ... of Premier Inc.,s Supplier Horizon Award . ... this year, Guerbet was recognized for its support of ... value creation through clinical excellence, and commitment to lower ... delighted to receive this recognition of our outstanding customer ...
Breaking Medicine Technology: